Adding the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib to the immune checkpoint inhibitor avelumab did not result in the extension of the clinical activity of either agent used as a monotherapy for most patients. However, a subset of patients benefited from the combination treatment, highlighting the need for optimised patient selection....